Xeris Biopharma director Jeffrey Sherman retiring at 2026 annual meeting

Filed April 21, 2026 · Period ending April 20, 2026 · ~1 min read

Key Changes

• low

  Dr. Jeffrey Sherman, a board member since 2021 serving on Compensation and Nominating committees, will retire and not seek reelection at the 2026 Annual Meeting.

  Item 5.02 verify on EDGAR →
• low

  Board size will reduce from eight to seven directors effective at the annual meeting; the company is not replacing Sherman's seat.

  Item 5.02 verify on EDGAR →
• low

  Company disclosed Sherman's retirement is not due to any disagreement with management or company operations, indicating an amicable departure.

  Item 5.02 verify on EDGAR →